biostudies-literatureKhairkhah NNational Institute of Neurological Disorders and StrokeNational Institutes of HealthChadtough Foundation101278https://www.ebi.ac.uk/biostudies/studies/S-EPMC12918168biostudies-literatureUnknown73<h4>Introduction</h4>Diffuse midline glioma (DMG) with the H3K27M mutation remains one of the most treatment-resistant pediatric brain tumors, in part due to limited antigen presentation and immune visibility. Exploring how glioma biology and therapeutic interventions influence immune recognition offers new opportunities to identify tumor-specific immune targets.<h4>Materials and methods</h4>We performed immunopeptidomics on human cell line derived tumor tissue for DMG and glioblastoma (GBM) and defined how MTX-241F, a selective EGFR/PI3K inhibitor, changes the tumor immunopeptidome. Immunopeptides were isolated from xenografted tumors by capturing MHC-I bound peptides followed by mass spectrometry. Comparative analyses were performed across tumor type (DMG vs. GBM) and treatment conditionNeoplasia (New York, N.Y.)Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).PMC129181681R01NS13151501Nyayapathy SOwolabi HRumble JMSebolt-Leopold JSIbrahim MMHNamvar AEverest-Dass AKhairkhah NJones RGalban SWhitehead CEfalseIdentification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).<h4>Introduction</h4>Diffuse midline glioma (DMG) with the H3K27M mutation remains one of the most treatment-resistant pediatric brain tumors, in part due to limited antigen presentation and immune visibility. Exploring how glioma biology and therapeutic interventions influence immune recognition offers new opportunities to identify tumor-specific immune targets.<h4>Materials and methods</h4>We performed immunopeptidomics on human cell line derived tumor tissue for DMG and glioblastoma (GBM) and defined how MTX-241F, a selective EGFR/PI3K inhibitor, changes the tumor immunopeptidome. Immunopeptides were isolated from xenografted tumors by capturing MHC-I bound peptides followed by mass spectrometry. Comparative analyses were performed across tumor type (DMG vs. GBM) and treatment condition2026-01-01T00:00:00Z2026 Feb2026-07-16T09:22:05.587Z2026-07-09T10:47:11.595ZS-EPMC129181684164329310.1016/j.neo.2026.101278